Heparin affin regulatory peptide/pleiotrophin negatively affects diverse biological activities in C6 glioma cells

European Journal of Cell Biology

Volumn 87, Issue 1, 2008, Pages 17-29

  Parthymou, Anastasia ^a   Lampropoulou, Evgenia ^a   Mikelis, Constantinos ^a   Drosou, Georgia ^a   Papadimitriou, Evangelia ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Angiogenesis; Endothelial cells; Glioblastoma; Glioma cells; Heparin affin regulatory peptide; Pleiotrophin; Tumor; Vascular endothelial growth factor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PLEIOTROPHIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL ACTIVITY; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSPLANTATION; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE COURSE; EMBRYO; ENDOTHELIUM CELL; GENETIC TRANSFECTION; GLIOMA; GLIOMA CELL; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION;

RATTUS;

EID: 37049007249     PISSN: 01719335     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcb.2007.07.007     Document Type: Article

References (46)

1. Adamsky K., Schilling J., Garwood J., Faissner A., and Peles E. Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase beta (RPTPbeta) to tenascin C. Oncogene 20 (2001) 609-618
2. Blazquez C., Gonzalez-Feria L., Alvarez L., Haro A., Casanova M.L., and Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 64 (2004) 5617-5623
3. Blondet B., Carpentier G., Ferry A., and Courty J. Exogenous pleiotrophin applied to lesioned nerve impairs muscle reinnervation. Neurochem. Res. 31 (2006) 907-913
4. Calvet L., Geoerger B., Regairaz M., Opolon P., Machet L., Morizet J., Joseph J.M., Elie N., and Vassal G. Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan. Oncogene 25 (2006) 3150-3159
5. Chauhan A.K., Li Y.S., and Deuel T.F. Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc. Nat. Acad. Sci. USA 90 (1993) 679-682
6. Chen H., Rubin E., Zhang H., Chung S., Jie C.C., Garrett E., Biswal S., and Sukumar S. Identification of transcriptional targets of HOXA5. J. Biol. Chem. 280 (2005) 19373-19380
7. Corbley M.J. Transformation by ras suppresses expression of the neurotrophic growth factor pleiotrophin. J. Biol. Chem. 272 (1997) 24696-24702
8. Czubayko F., Schulte A.M., Berchem G.J., and Wellstein A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc. Nat. Acad. Sci. USA 93 (1996) 14753-14758
9. Dirks W.G., Fahnrich S., Lis Y., Becker E., MacLeod R.A., and Drexler H.G. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int. J. Cancer 100 (2002) 49-56
10. Gilbert M.R., and Loghin M. The treatment of malignant gliomas. Curr. Treat. Options Neurol. 7 (2005) 293-303
11. Grzelinski M., Bader N., Czubayko F., and Aigner A. Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int. J. Cancer 117 (2005) 942-951
12. Hatziapostolou M., Delbe J., Katsoris P., Polytarchou C., Courty J., and Papadimitriou E. Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity. Prostate 65 (2005) 151-158
13. Hatziapostolou M., Polytarchou C., Katsoris P., Courty J., and Papadimitriou E. Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells. J. Biol. Chem. 281 (2006) 32217-32226
14. Heroult M., Bernard-Pierrot I., Delbe J., Hamma-Kourbali Y., Katsoris P., Barritault D., Papadimitriou E., Plouet J., and Courty J. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene 23 (2004) 1745-1753
15. Hienola A., Pekkanen M., Raulo E., Vanttola P., and Rauvala H. HB-GAM inhibits proliferation and enhances differentiation of neural stem cells. Mol. Cell. Neurosci. 26 (2004) 75-88
16. Ke L.D., Shi Y.X., and Yung W.K. VEGF(121), VEGF(165) overexpression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells. Cancer Res. 62 (2002) 1854-1861
17. Lu K.V., Jong K.A., Kim G.Y., Singh J., Dia E.Q., Yoshimoto K., Wang M.Y., Cloughesy T.F., Nelson S.F., and Mischel P.S. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J. Biol. Chem. 280 (2005) 26953-26964
18. Mentlein R., and Held-Feindt J. Pleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomas. J. Neurochem. 83 (2002) 747-753
19. Merenmies J. Cell density-dependent expression of heparin-binding growth-associated molecule (HB-GAM, p18) and its down-regulation by fibroblast growth factors. FEBS Lett. 307 (1992) 297-300
20. Mikelis C., Koutsioumpa M., and Papadimitriou E. Pleiotrophin as a possible new target for angiogenesis-related diseases and cancer. Recent Patents Anti-Cancer Drug Discovery 2 (2007) 175-186
21. Millauer B., Shawver L.K., Plate K.H., Risau W., and Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367 (1994) 576-579
22. Moog-Lutz C., Degoutin J., Gouzi J.Y., Frobert Y., Brunet-de Carvalho N., Bureau J., Creminon C., and Vigny M. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem. 280 (2005) 26039-26048
23. Motegi A., Fujimoto J., Kotani M., Sakuraba H., and Yamamoto T. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J. Cell Sci. 117 (2004) 3319-3329
24. Muller S., Lamszus K., Nikolich K., and Westphal M. Receptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy. Expert Opin. Ther. Targets 8 (2004) 211-220
25. Nakagawa T., Kubota T., Ido K., Sakuma T., and Matsuda K. Gene expression profiles of 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU)-resistant C6 rat glioma cells. J. Neurooncol. 79 (2006) 271-279
26. Niola F., Evangelisti C., Campagnolo L., Massalini S., Bue M.C., Mangiola A., Masotti A., Maira G., Farace M.G., and Ciafre S.A. A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol. Ther. 5 (2006) 174-179
27. Papadimitriou E., Heroult M., Courty J., Polykratis A., Stergiou C., and Katsoris P. Endothelial cell proliferation induced by HARP: implication of N or C terminal peptides. Biochem. Biophys. Res. Commun. 274 (2000) 242-248
28. Papadimitriou E., Polykratis A., Hatziapostolou M., Parthymou A., Polytarchou C., and Mikelis C. Heparin affin regulatory peptide: a new target for tumour therapy?. Curr. Cancer Drug Targets 4 (2004) 471-482
29. Parthymou A., Kardamakis D., Pavlopoulos I., and Papadimitriou E. Irradiated C6 glioma cells induce angiogenesis in vivo and activate endothelial cells in vitro. Int. J. Cancer 110 (2004) 807-814
30. Peles E., Schlessinger J., and Grumet M. Multi-ligand interactions with receptor-like protein tyrosine phosphatase beta: implications for intercellular signalling. Trends Biochem. Sci. 23 (1998) 121-124
31. Perez-Pinera P., Alcantara S., Dimitrov T., Vega J.A., and Deuel T.F. Pleiotrophin disrupts calcium-dependent homophilic cell-cell adhesion and initiates an epithelial-mesenchymal transition. Proc. Nat. Acad. Sci. USA 103 (2006) 17795-17800
32. Polykratis A., Delbe J., Courty J., Papadimitriou E., and Katsoris P. Identification of heparin affin regulatory peptide domains with potential role on angiogenesis. Int. J. Biochem. Cell Biol. 36 (2004) 1954-1966
33. Polytarchou C., Hatziapostolou M., and Papadimitriou E. Hydrogen peroxide stimulates proliferation and migration of human prostate cancer cells through activation of activator protein-1 and up-regulation of the heparin affin regulatory peptide gene. J. Biol. Chem. 280 (2005) 40428-40435
34. Powers C., Aigner A., Stoica G.E., McDonnell K., and Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J. Biol. Chem. 277 (2002) 14153-14158
35. Reardon D.A., Rich J.N., Friedman H.S., and Bigner D.D. Recent advances in the treatment of malignant astrocytoma. J. Clin. Oncol. 24 (2006) 1253-1265
36. Reni M., Mazza E., Tosoni A., and Brandes A.A. Novel therapeutics in adult malignant brain gliomas. Expert Opin. Investig. Drugs 14 (2005) 643-658
37. Rhoads K., Arderiu G., Charboneau A., Hansen S.L., Hoffman W., and Boudreau N. A role for HoxA5 in regulating angiogenesis and vascular patterning. Lymphat. Res. Biol. 3 (2005) 240-252
38. Saleh M., Stacker S.A., and Wilks A.F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56 (1996) 393-401
39. Shirsat N.V., and Shaikh S.A. Overexpression of the immediate early gene fra-1 inhibits proliferation, induces apoptosis, and reduces tumourigenicity of C6 glioma cells. Exp. Cell Res. 291 (2003) 91-100
40. Steiner H.H., Karcher S., Mueller M.M., Nalbantis E., Kunze S., and Herold-Mende C. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J. Neurooncol. 66 (2004) 129-138
41. Ulbricht U., Eckerich C., Fillbrandt R., Westphal M., and Lamszus K. RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J. Neurochem. 98 (2006) 1497-1506
42. Vajkoczy P., Schilling L., Ullrich A., Schmiedek P., and Menger M.D. Characterization of angiogenesis and microcirculation of high-grade glioma: an intravital multifluorescence microscopic approach in the athymic nude mouse. J. Cereb. Blood Flow Metab. 18 (1998) 510-520
43. Weber D., Klomp H.J., Czubayko F., Wellstein A., and Juhl H. Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. Cancer Res. 60 (2000) 5284-5288
44. Wu M., Gan K., Huang C., Tang Y., Chen Q., Tang K., Li X., Shen S., and Li G. LRRC4 controls in vitro invasion of glioblastoma cells through inhibiting RPTP-zeta expression. J. Neurooncol. 80 (2006) 133-142
45. Zhang N., Zhong R., Wang Z.Y., and Deuel T.F. Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant. J. Biol. Chem. 272 (1997) 16733-16736
46. Zhang L., Mabuchi T., Satoh E., Maeda S., Nukui H., and Naganuma H. Overexpression of heparin-binding growth-associated molecule in malignant glioma cells. Neurol. Med. Chir. (Tokyo) 44 (2004) 637-643